Analyst Sentiment Shifts to Cautious Stance on Tilray Shares

Market observers are adopting a more guarded outlook on Tilray Brands, Inc. The latest signal came from Wall Street Zen, which revised its rating on the stock from “Sell” to “Hold.” This adjustment aligns with a broader trend of increasing analyst caution surrounding the cannabis and beverage company.

Financial Performance and Market Position

The company’s recent quarterly report for Q2 of fiscal year 2026 (period ending November 30, 2025) revealed revenue of $217.5 million. However, the financial metrics showed challenges, including a net margin of -251.69% and a return on equity (ROE) of -6.35%. The price-to-earnings (P/E) ratio stands at -0.35.

From a liquidity perspective, Tilray reports a current ratio of 2.81 and a quick ratio of 1.72. Its debt-to-equity ratio is 0.19.

Trading activity on Friday saw the shares close at $7.75, down from the previous day’s close of $7.89. The stock moved between an intraday low of $7.66 and a high of $7.99, with a trading volume of 2.54 million shares. Notably, the current price sits below key technical indicators, trading under both the 50-day moving average of $9.10 and the 200-day moving average of $11.04. This chart pattern suggests continued downward pressure. With a beta of 2.02, the equity is considered to have above-average volatility. Its 52-week range spans from $3.51 to $23.20, and its market capitalization is approximately $903 million.

Should investors sell immediately? Or is it worth buying Tilray?

The Evolving Analyst Consensus

The overall analyst landscape is now characterized by restraint. Current recommendations consist of one “Buy,” six “Hold,” and one “Sell” rating. The average price target among analysts is $13.33 per share.

Wall Street Zen’s upgrade follows similar reassessments by other firms. On February 11, Zacks upgraded its rating from “Strong Sell” to “Hold.” In late January, Canaccord Genuity initiated coverage with a “Hold” recommendation. Roth MKM maintained a “Neutral” stance but significantly reduced its price target from $20.00 to $10.00. ATB Cormark also raised its view, moving from “Strong Sell” to “Hold.”

Strategic Developments: The Carlsberg Partnership

On the operational front, Tilray announced a significant development on February 18. The company entered into an exclusive, five-year licensing agreement with the Carlsberg Group. Scheduled to commence on January 1, 2027, the deal grants Tilray the rights to produce, market, and distribute Carlsberg, Carlsberg Elephant, and Kronenbourg 1664 Blanc brands in the United States. According to the company’s statement, it plans to leverage its existing brewing capacity and national distribution network to execute this partnership.

The collective picture that emerges is one of tempered expectations. Repeated upgrades to “Hold,” coupled with reduced price targets from some analysts and a stock price languishing below key averages, indicate persistent caution. While the Carlsberg agreement provides a long-term strategic perspective, its tangible impact on the U.S. market will not begin until 2027.